167 related articles for article (PubMed ID: 22069683)
1. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
3. Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2.
Backer MV; Budker VG; Backer JM
J Control Release; 2001 Jul; 74(1-3):349-55. PubMed ID: 11489517
[TBL] [Abstract][Full Text] [Related]
4. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins.
Backer MV; Backer JM
Bioconjug Chem; 2001; 12(6):1066-73. PubMed ID: 11716701
[TBL] [Abstract][Full Text] [Related]
5. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
6. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
7. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
9. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
10. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
11. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
14. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155.
Ueda Y; Yamagishi T; Samata K; Hirayama N; Aozuka Y; Tanaka M; Nakaike S; Saiki I
Anticancer Res; 2005; 25(6B):3973-7. PubMed ID: 16309186
[TBL] [Abstract][Full Text] [Related]
17. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature.
Backer MV; Gaynutdinov TI; Patel V; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Barth RF; Claffey K; Backer JM
Mol Cancer Ther; 2005 Sep; 4(9):1423-9. PubMed ID: 16170035
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Kim LS; Huang S; Lu W; Lev DC; Price JE
Clin Exp Metastasis; 2004; 21(2):107-18. PubMed ID: 15168728
[TBL] [Abstract][Full Text] [Related]
20. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]